术前放化疗联合PD-1抑制剂治疗溃疡性结肠炎相关性结直肠癌的疗效观察

Zhao Yangcheng; Shan Liuqun; Cheng Gongming; Ding Yongbin

doi:10.3969/j.issn.1003-5591.2025.02.006

您当前的位置：

首页 >

文章列表页 >

术前放化疗联合PD-1抑制剂治疗溃疡性结肠炎相关性结直肠癌的疗效观察

更新时间：2026-11-05

- 术前放化疗联合PD-1抑制剂治疗溃疡性结肠炎相关性结直肠癌的疗效观察
- J Abdominal Surg Vol. 38, Issue 2, Pages: 118-122(2025)
- 作者机构：
  
  1.南京医科大学第一附属医院普外科，江苏南京 210029
  2.南京市第二医院普外科，江苏南京 210003
- 作者简介：
  
  Ding Yongbin， Email： njdyb@njmu.edu.cn
- 基金信息：
- DOI：10.3969/j.issn.1003-5591.2025.02.006
  CLC： R735.3
- Received：26 February 2024，
  
  Published：22 April 2025
- 稿件说明：
移动端阅览
赵阳程,单留群,程功名等.术前放化疗联合PD-1抑制剂治疗溃疡性结肠炎相关性结直肠癌的疗效观察[J].腹部外科,2025,38(02):118-122.

Zhao Yangcheng,Shan Liuqun,Cheng Gongming,et al.Preoperative chemoradiotherapy combined with PD-1 inhibitors in treating ulcerative colitis-associated colorectal cancer： an efficacy evaluation[J].J Abdominal Surg,2025,38(02):118-122.
赵阳程,单留群,程功名等.术前放化疗联合PD-1抑制剂治疗溃疡性结肠炎相关性结直肠癌的疗效观察[J].腹部外科,2025,38(02):118-122. DOI： 10.3969/j.issn.1003-5591.2025.02.006.

Zhao Yangcheng,Shan Liuqun,Cheng Gongming,et al.Preoperative chemoradiotherapy combined with PD-1 inhibitors in treating ulcerative colitis-associated colorectal cancer： an efficacy evaluation[J].J Abdominal Surg,2025,38(02):118-122. DOI： 10.3969/j.issn.1003-5591.2025.02.006.

摘要

目的

探讨术前新辅助放化疗联合程序性死亡受体1（programmed cell death-1，PD-1）抑制剂治疗溃疡性结肠炎相关性结直肠癌（ulcerative colitis related colorectal cancer，UCRCC）的近期效果。

方法

回顾性收集2021年3月至2023年12月于南京市第二医院接受PD-1抑制剂联合新辅助放化疗并进行手术的UCRCC病人的临床资料。根据术前治疗方案分为对照组（

=46）和联合组（

=34）。对照组术前病人仅接受卡培他滨+奥沙利铂方案化疗2个周期，休息2周后再进行2周期的放疗；联合组病人在对照组基础上术前给予PD-1抑制剂，每3周1次，共2周期。两组病人新辅助放化疗结束后4～6周行手术治疗，结直肠全切+回肠造瘘或肠道肿瘤根治术。比较两组病人新辅助治疗效果、肿瘤标志物水平、药物不良

反应情况、围手术期相关指标水平以及术后病理情况。

结果

联合组疾病控制率显著高于对照组（

＜0.05）。联合组糖类抗原242、糖类抗原72-4、癌胚抗原、糖类抗原19-9水平显著低于对照组（

＜0.05），肿瘤退缩分级0级和1级的比例显著高于对照组。两组病人不良反应发生率和围手术期相关指标比较无显著差异（

＞0.05）。

结论

术前新辅助放化疗联合PD-1抑制剂对UCRCC的控制效果良好，可降低病人肿瘤标志物水平，改善病人术后病理情况，具有一定安全性。

Abstract

Objective

To investigate the short-term effect of preoperative neoadjuvant chemoradiotherapy combined with programmed cell death 1 （PD-1） inhibitors on the treatment of ulcerative colitis related colorectal cancer （UCRCC）.

Methods

Clinical data of UCRCC patients who received PD-1 inhibitors combined with neoadjuvant therapy and surgically operated in the Second Hospital of Nanjing from March 2021 to December 2023 were retrospectively collected. Patients were divided into the control group （

=46） and combination group （

=34） based on preoperative treatment regimens. Patients in the control group received two cycles of capecitabine + oxaliplatin chemotherapy preoperatively， followed by two cycles of radiotherapy after a 2-week rest. Those in the combination group received PD-1 inhibitors every 3 weeks for two cycles， plus clinical management as the same as in the control group. All patients underwent surgery （total colorectal resection with ileostomy or radical intestinal tumor resection） 4-6 weeks after neoadjuvant chemoradiotherapy. The effect of neoadjuvant therapy， tumor markers， drug toxicity， side effects， perioperative indicators and postoperative pathology were compared between the two groups.

Results

Disease control rate in the combination group was significantly higher than that of the control group （

＜0.05）. The levels of carbohydrate antigen 242， carbohydrate antigen 72-4， carcinoembryonic antigen and carbohydrate antigen 199 in the combination group were sign

ificantly lower than those of the control group （

＜0.05）， and the percentage of tumor regression grades 0 and 1 was significantly higher compared to the control group. There were no significant differences in the incidence of toxic and side effects and perioperative indexes between the two groups （

0.05）.

Conclusion

Preoperative neoadjuvant chemoradiotherapy combined with PD-1 inhibitors demonstrates favorable efficacy in controlling UCRCC， reducing tumor marker levels， improving postoperative pathological outcomes， and exhibiting an acceptable safety profile.

关键词

Keywords

references

滕熠，张晓丹，夏昌发，等 . 中国与全球癌症发病、死亡和患病对比及其预测分析：GLOBOCAN 2022数据解读［J］. 中华肿瘤防治杂志， 2024 ， 31 （ 23 ）： 1413 - 1420 . DOI： 10.16073/j.cnki.cjcpt.2024.23.01 http://dx.doi.org/10.16073/j.cnki.cjcpt.2024.23.01 .

中华医学会外科学分会结直肠外科学组 . 结直肠癌多学科综合治疗协作组诊疗模式中国专家共识（2023版）［J］. 中国实用外科杂志， 2024 ， 44 （ 1 ）： 1 - 16 . DOI： 10.19538/j.cjps.issn1005-2208.2024.01.01 http://dx.doi.org/10.19538/j.cjps.issn1005-2208.2024.01.01 .

马盛哲 . 微卫星稳定型直肠癌新辅助放化疗联合免疫治疗的研究进展［J］. 肿瘤， 2023 ， 43 （ 5 ）： 411 - 420 . DOI： 10.3781/j.issn.1000-7431.2023.2306-0317 http://dx.doi.org/10.3781/j.issn.1000-7431.2023.2306-0317 .

袁之俊，来茂德 . 结直肠癌分子分型与免疫治疗和靶向治疗［J］. 临床与实验病理学杂志， 2024 ， 40 （ 6 ）： 561 - 566 . DOI： 10.13315/j.cnki.cjcep.2024.06.001 http://dx.doi.org/10.13315/j.cnki.cjcep.2024.06.001 .

Sui QQ ， Zhang X ， Chen C ， et al . Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer ［J］. Nat Commun ， 2022 ， 13 （ 1 ）： 7316 . DOI： 10.1038/s41467-022-35096-6 http://dx.doi.org/10.1038/s41467-022-35096-6 .

汪泓，罗文广，张红雁，等 . 直肠癌新辅助放化疗后病理完全缓解的临床预测因素分析［J］. 安徽医学， 2024 ， 45 （ 9 ）： 1100 - 1105 . DOI： 10.3969/j.issn.1000-0399.2024.09.005 http://dx.doi.org/10.3969/j.issn.1000-0399.2024.09.005 .

朱智云，王德平，张兴飞 . 我院新型抗肿瘤药物医嘱点评及用药分析［J］. 肿瘤药学， 2024 ， 14 （ 3 ）： 368 - 372 . DOI： 10.3969/j.issn.2095-1264.2024.03.15 http://dx.doi.org/10.3969/j.issn.2095-1264.2024.03.15 .

李杉，柳艳飞，刘倩，等 . 呋喹替尼联合信迪利单抗治疗晚期微卫星稳定型结直肠癌疗效观察［J］. 肿瘤防治研究， 2023 ， 50 （ 12 ）： 1227 - 1231 . DOI： 10.3971/j.issn.1000-8578.2023.23.0578 http://dx.doi.org/10.3971/j.issn.1000-8578.2023.23.0578 .

朱麒，刘迁，肖敏，等 . 信迪利单抗联合呋喹替尼治疗微卫星稳定型晚期结肠癌患者的临床疗效及对患者免疫功能的影响［J］. 中国免疫学杂志， 2023 ， 39 （ 9 ）： 1922 - 1927 . DOI： 10.3969/j.issn.1000-484X.2023.09.021 http://dx.doi.org/10.3969/j.issn.1000-484X.2023.09.021 .

Dong P ， Wei WS ， Jiang LJ ， et al . Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma （nccRR）：Preliminary results from an exploratory prospective multicentre clinical study ［J］. J Clin Oncol ， 2024 ， 42 （ 16_suppl ）： 4544 . DOI： 10.1200/jco.2024.42.16_suppl.4544 http://dx.doi.org/10.1200/jco.2024.42.16_suppl.4544 .

Xu Q ， Wang JJ ， Sun Y ， et al . Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer：a multicenter，single-arm，prospective phase II trial ［J］. J Clin Oncol ， 2022 ， 40 （ 16 ）： 1795 - 1805 . DOI： 10.1200/JCO.21.02091 http://dx.doi.org/10.1200/JCO.21.02091 .

徐锰超，谢玉玺，邵元伟 . 磁共振弥散加权成像ADC值联合血清肿瘤标志物对结直肠癌患者术后复发转移的预测价值［J］. 中国CT和MRI杂志， 2024 ， 22 （ 1 ）： 137 - 140 .

李春霞，游瑞敏，刘丽珠，等 . CA242围手术期变化模式及纵向轨迹与结直肠癌预后的关联：一项回顾性纵向队列研究［J］. 科学通报（英文版）， 2023 ， 68 （ 17 ）： 1875 - 1879 .

田洁，付文华，张媛，等 . 恩度联合信迪利单抗注射液治疗晚期结直肠癌的效果及其对血清CA199、CEA、CYFRA21-1水平的影响［J］. 分子诊断与治疗杂志， 2023 ， 15 （ 5 ）： 897 - 900 . DOI： 10.19930/j.cnki.jmdt.2023.05.025 http://dx.doi.org/10.19930/j.cnki.jmdt.2023.05.025 .

Vitale E ， Rizzo A ， Maistrello L ， et al . Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors：the MOUSEION-07 systematic review and meta-analysis ［J］. Sci Rep ， 2024 ， 14 ： 28309 . DOI： 10.1038/s41598-024-71746-z http://dx.doi.org/10.1038/s41598-024-71746-z .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploration and application prospects of 5G-enabled telerobotic surgery in the treatment of cholangiocarcinoma

Current status of classification and comprehensive treatments for intrahepatic cholangiocarcinoma

Comprehensive management of MASLD in metabolic bariatric surgery： separate evaluation of weight-loss efficacy and hepatic risk and stratified decision-making

Malnutrition after one-anastomosis gastric bypass： balancing weight-loss efficacy and nutritional risk

十二指肠穿透性溃疡致肝脏粘连假性占位伴大出血1例

Related Author

Pu Baohong

Liu Peng

Cui Jiaming

Gou Tongtong

Ma Shixun

Tian Hongwei

Ma Shihui

Cui Yunfu

Related Institution

First Clinical Medical School， Gansu University of Chinese Medicine

Department of General Surgery， Gansu Provincial Hospital

Department of Biliary & Pancreatic Surgery， Second Affiliated Hospital， Harbin Medical University

AI问答

⁰